Researchers found that uptake of infliximab biosimilars in the United States increased significantly after the third biosimilar became available in July 2020. However, Medicare prescriptions still lag behind private insurance and Medicaid. The study analyzed data from over 1100 rheumatologists from April 2016 to September 2022. By September 2022, biosimilar uptake was higher for Medicaid and private insurance than for Medicare. The researchers suggest that policymakers may need to incentivize the development and entry of multiple biosimilars to ensure a competitive and sustainable market that reduces drug expenditures. The study was led by Eric T. Roberts, PhD, from the University of California San Francisco and published in Arthritis & Rheumatology in July 2024.
Source link
Infliximab Biosimilars Uptake in US Reveals Ongoing Concerns
